SAN DIEGO, April 15 /PRNewswire-FirstCall/ -- SGX Pharmaceuticals, Inc. (Nasdaq: SGXP) presented abstract #4844 at the 2008 Annual Meeting of the American Association for Cancer Research (AACR) in San Diego. The poster entitled "SGX523, a potent and exquisitely selective inhibitor of the HGF receptor tyrosine kinase (MET), inhibits growth of human glioblastoma tumors in a mouse model," was presented in the afternoon poster session entitled Small Molecule Kinase Inhibitors 1 in Exhibit Hall B-F.
SGX's MET program comprises potent, selective ATP-competitive MET inhibitors, from which a number of drug-like compounds have been identified. The first development candidate, SGX523, demonstrated potent anti-tumor activity when dosed orally in various mouse models of human cancer including glioblastoma, gastric cancer and lung cancer. SGX's second development candidate, SGX126, is structurally distinct and may possess several advantages over SGX523, including the potential for a lower human dose.
"We are continuing to progress SGX126 towards IND submission, while evaluating additional follow-on compounds for our MET program," said Mike Grey, the CEO of SGX Pharmaceuticals.
About SGX Pharmaceuticals
SGX Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development and commercialization of novel, targeted therapeutics directed at addressing unmet medical needs in oncology. Our drug development programs target the MET receptor tyrosine kinase, an enzyme implicated in a broad array of cancers, and the BCR-ABL tyrosine kinase enzyme for the treatment of Chronic Myelogenous Leukemia, or CML. Our drug discovery activities are focused on a portfolio of other protein and enzyme targets that have been implicated in human cancers including JAK2 and RAS. More information on the pipeline and drug discovery platform can be found at http://www.sgxpharma.com and in the Company's various filings with the Securities and Exchange Commission.
Forward Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include, but are not limited to, statements related to the Company's MET program and the advancement of the Company's drug development and discovery pipeline. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug discovery, development and commercialization, which include, without limitation, the potential failure of development candidates to advance through preclinical studies or demonstrate safety and efficacy in clinical testing and the ability to file INDs in the referenced time frames. The results of early preclinical studies or clinical trials may not be predictive of future results, and the Company cannot provide any assurances that any of its compounds or development candidates will have favorable results in preclinical studies or clinical trials. For a discussion of these and other factors, please refer to the risk factors described in the Company's annual report on Form 10-K for the year ended December 31, 2007, as well as other filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and SGX undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
|SOURCE SGX Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved